A histidine acid phosphatase from the CDC Category A pathogen F. tularensis has been crystallized in space group P41212, with unit-cell parameters a = 61.96, c = 210.78 Å. A 1.75 Å resolution data set was collected at Advanced Light Source beamline 4.2.2.
Keywords: Francisella tularensis, acid phosphatases, histidine acid phosphatases, Legionella pneumophila major acid phosphatase, human prostatic acid phosphatase, RHGXRXP motif
Abstract
Francisella tularensis is a highly infectious bacterial pathogen that is considered by the Centers for Disease Control and Prevention to be a potential bioterrorism weapon. Here, the crystallization of a 37.2 kDa phosphatase encoded by the genome of F. tularensis subsp. holarctica live vaccine strain is reported. This enzyme shares 41% amino-acid sequence identity with Legionella pneumophila major acid phosphatase and contains the RHGXRXP motif that is characteristic of the histidine acid phosphatase family. Large diffraction-quality crystals were grown in the presence of Tacsimate, HEPES and PEG 3350. The crystals belong to space group P41212, with unit-cell parameters a = 61.96, c = 210.78 Å. The asymmetric unit is predicted to contain one protein molecule, with a solvent content of 53%. A 1.75 Å resolution native data set was recorded at beamline 4.2.2 of the Lawrence Berkeley National Laboratory Advanced Light Source. Molecular-replacement trials using the human prostatic acid phosphatase structure as the search model (28% amino-acid sequence identity) did not produce a satisfactory solution. Therefore, the structure of F. tularensis histidine acid phosphatase will be determined by multiwavelength anomalous dispersion phasing using a selenomethionyl derivative.
1. Introduction
Francisella tularensis is a Gram-negative facultative intracellular coccobacillus that causes the zoonotic disease tularemia (Ellis et al., 2002 ▶). The organism grows readily in broth culture, it can be isolated from numerous rodent and arthropod vectors and it is highly infectious (Dennis et al., 2001 ▶; Oyston et al., 2004 ▶). Ulceroglandular tularemia results from infections acquired through the skin or mucous membranes. Of chief concern in the context of biodefense is the possibility of infection by inhalation of the aerosolized pathogen, which results in the pneumonic form of the disease (Dennis et al., 2001 ▶). Inhalation tularemia is by far the most dangerous form of tularemia and has a case fatality rate of up to 30% if untreated (Oyston et al., 2004 ▶). Accordingly, the Centers for Disease Control and Prevention have designated F. tularensis to be a Category A pathogen, a class that includes the causative pathogens of anthrax, botulism, plague and smallpox. Thus, there is renewed interest in understanding the basic biochemistry and biology of F. tularensis in order to facilitate development of improved vaccines and antimicrobial agents that will provide protection and treatment in the event of a Francisella-based attack.
As part of our ongoing research on the roles of phosphatases in F. tularensis intracellular survival and virulence (Baron et al., 1999 ▶; Reilly et al., 1996 ▶, 2006 ▶; Felts et al., 2005 ▶), we analyzed the complete but unannotated genome sequence of F. tularensis subsp. holarctica live vaccine strain (LVS) in search of possible phosphatase genes. Comparison of the open reading frames of the LVS genome with current sequence databases using BLAST (Altschul et al., 1990 ▶) identified a 37.2 kDa ortholog of the major acid phosphatase from Legionella pneumophila (MAP; Aragon et al., 2001 ▶). The deduced amino-acid sequence of the F. tularensis protein is 41% identical (134 out of 330 residues) to that of MAP (Fig. 1 ▶) and exhibited lower but significant homology to several phosphatases from eukaryotic sources. These enzymes share the conserved RHGXRXP motif (Fig. 1 ▶) characteristic of the histidine acid phosphatase (HAP) family (Van Etten et al., 1991 ▶).
MAP is thought to be secreted via the type II secretion system and may be involved in intracellular infection (Aragon et al., 2001 ▶). It is not known whether F. tularensis HAP (FtHAP) is secreted by an analogous system or whether FtHAP plays a role in virulence or intracellular survival. In parallel with our studies of substrate specificity, kinetics and biological function of this newly discovered enzyme, we have crystallized FtHAP as a first step toward structure determination.
2. Methods and results
2.1. Cloning, expression and protein purification
The hap gene was amplified by PCR from genomic DNA obtained from the F. tularensis subsp. holarctica live vaccine strain and cloned into pET20b (Novagen) using NcoI and XhoI sites. The recombinant protein was expressed in Escherichia coli using procedures similar to those described previously for the AcpA phosphatase (Reilly et al., 2006 ▶). Harvested cells were resuspended in 50 mM sodium acetate pH 6.0 (buffer A) and lysed in a French pressure cell. The resulting mixture exhibited strong phosphatase activity as measured by a discontinuous colorimetric activity assay using p-nitrophenylphosphate as the substrate (Reilly et al., 1999 ▶). This assay was also performed after each step in the following purification procedure to identify the enzyme of interest and its relative activity in the collected fractions. Sodium chloride was added to the broken cells to a final concentration of 1.0 M and two centrifugation cycles of (i) 27 200g for 20 min and (ii) 184 000g for 1.5 h were performed. The supernatant from the latter centrifugation step was dialyzed against buffer A for 24 h. The sample was applied onto a HiTrap SP HP cation-exchange column (Amersham Biosciences) that had been equilibrated with buffer A. A linear NaCl gradient of 0–1.0 M over eight column volumes was used to elute the protein from the column. FtHAP was eluted at 500 mM NaCl. The protein was then dialyzed against 10 mM Na3PO4 pH 7.0 (buffer B) for 24 h. The dialyzed sample was applied onto a HiTrap Chelating HP column (Amersham Biosciences) that had been charged with 0.1 M NiSO4 and equilibrated with buffer B. A linear imidazole gradient of 0–1.0 M was used to elute the protein from the column. FtHAP eluted at 350 mM imidazole. The protein was then dialyzed against buffer A for 24 h and concentrated to 10 mg ml−1. Protein concentration was determined by absorption spectroscopy using an extinction coefficient (λ = 280 nm) of 48 360 M −1 cm−1 predicted by the ExPASy server (Gasteiger et al., 2005 ▶). Protein purity was evaluated by SDS–PAGE.
2.2. Crystallization
Crystallization trials were performed using the sitting-drop method of vapor diffusion at 293 K. Initial screening for crystallization conditions was performed using the Index Screen from Hampton Research. Equal volumes of the protein (1.5 µl) and the reservoir (1.5 µl) were mixed and allowed to equilibrate with 1.0 ml of reservoir for 24–48 h. Index Screen reagents 3–6, 21, 39, 42, 57, 63, 65, 67–69, 71, 72, 75–80, 83–85, 87, 92 and 94 produced crystals of various size and quality. Condition 63 produced the largest and most well defined crystals. This condition contained 5%(v/v) Tacsimate, 0.1 M HEPES pH 7.0 and 25%(w/v) PEG 3350. Tacsimate (Hampton Research, HR2-755) is a mixture of organic acids that includes sodium malonate, sodium acetate, triammonium citrate, succinic acid, dl-malic acid and sodium formate (Bob Cudney, personal communication). The initial crystals were diamond-shaped with jagged edges and in some cases multiple crystals were fused together (Fig. 2 ▶ a). One round of optimization resulted in large single crystals having sharp edges and dimensions of 0.4 × 0.4 × 0.7 mm (Fig. 2 ▶ b). The final optimized condition contained 10%(v/v) Tascimate, 0.1 M HEPES pH 7.0 and 19%(w/v) PEG 3350. These crystals typically appeared within 48 h of setup.
The crystals were cryoprotected in the harvest buffer [10%(v/v) Tacsimate, 0.1 M HEPES pH 7.0, 24% PEG 3350] supplemented with 25% PEG 200 as follows. Firstly, 10–30 µl of harvest buffer was added to a sitting drop that contained crystals. Next, the liquid in the drop was exchanged for the cryoprotectant in five steps over a period of 10–20 min without moving the crystals. At each step, the concentration of PEG 200 was increased by 5% and the drop was gently mixed by aspiration without disturbing the crystals. Finally, the crystals were picked up with Hampton mounting loops and plunged into liquid nitrogen.
2.3. Data collection and processing
Initial characterization of X-ray diffraction was performed using an R-AXIS IV image-plate detector coupled to a Rigaku copper rotating-anode generator. Autoindexing of diffraction images using CrystalClear (Pflugrath, 1999 ▶) suggested a primitive tetragonal lattice with unit-cell parameters a = 62.0, c = 211.0 Å. Frozen crystals were transported to Lawrence Berkeley National Laboratory for high-resolution data collection at the Advanced Light Source (ALS).
Diffraction data were collected at ALS beamline 4.2.2 using a NOIR-1 detector with the detector distance and angle set to 150 mm and 17°, respectively. A total of 180° of data were collected using an oscillation angle of 0.5° and an exposure time of 8 s per image. The data were integrated and scaled to 1.75 Å resolution using d*TREK (Pflugrath, 1999 ▶). The refined unit-cell parameters were determined to be a = 61.96, c = 210.78 Å. Analysis of the data with dtcell (Pflugrath, 1999 ▶) suggested space group P41212. Matthews calculations suggested that this crystal form has one molecule in the asymmetric unit, 53% solvent content and a Matthews coefficient of 2.7 Å3 Da−1 (Matthews, 1968 ▶). See Table 1 ▶ for data-processing statistics.
Table 1. Data-collection and processing statistics.
Space group | P41212 |
Unit-cell parameters (Å) | a = 61.96, c = 210.78 |
Wavelength (Å) | 1.12718 |
Resolution range (Å) | 46.47–1.75 (1.81–1.75) |
Total reflections | 243916 |
Unique reflections | 41088 |
Redundancy | 5.94 (4.72) |
Mosaicity (°) | 0.466 |
Rmerge | 0.041 (0.299) |
Completeness (%) | 96.2 (91.7) |
Average I/σ(I) | 25.4 (5.2) |
Since the apparent Laue class is 4/mmm, the possibility of merohedral twinning was considered. A plot of the cumulative intensity distribution for acentric reflections did not display the sigmoidal shape characteristic of twinned data (Rees, 1980 ▶). The average value of 〈I 2(h)〉/〈I(h)〉2 was 2.2 for acentric reflections, which is close to the value of 2.0 expected for untwinned data (Redinbo & Yeates, 1993 ▶). For reference, a value of 1.5 is expected in the case of perfect hemihedral twinning (Redinbo & Yeates, 1993 ▶). Based on these results, we do not anticipate difficulties arising from twinning during structure determination.
The FtHAP sequence was compared with sequences in the Protein Data Bank (PDB; Berman et al., 2000 ▶) to identify a search model for molecular-replacement calculations. The closest relative in the PDB is human prostatic acid phosphatase (PDB code 1cvi; Jakob et al., 2000 ▶), which shares 28% global amino-acid sequence identity with FtHAP. Molecular-replacement trials were performed with MOLREP (Vagin & Teplyakov, 1997 ▶) using 1cvi as the search model. All possible space groups with Laue symmetry 4/mmm were tested. The top solution had R > 0.6 and correlation coefficient < 0.12, which indicated that molecular replacement is not a suitable phasing method. Structure determination using crystals of selenomethionyl FtHAP is in progress. 12 Met residues are expected in the asymmetric unit (Fig. 1 ▶).
Acknowledgments
This research was supported by National Institutes of Health grant U54 AI057160 to the Midwest Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research (MRCE, JJT and TJR), by the University of Missouri Research Board (JJT) and by a subproject of USDA-ARS Program for Prevention of Animal Infectious Diseases (PPAID), Advanced Technologies for Vaccines and Diagnostics (TJR) under cooperative agreement USDA-ARS 58-1940-5-519. We thank Jay Nix and Darren Sherrell for their assistance at ALS beamline 4.2.2. The Advanced Light Source is supported by the Director, Office of Science, Office of Basic Energy Sciences and Materials Sciences Division of the US Department of Energy under contract No. DE-AC03-76SF00098 at Lawrence Berkeley National Laboratory.
References
- Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. (1990). J. Mol. Biol.215, 403–410. [DOI] [PubMed] [Google Scholar]
- Aragon, V., Kurtz, S. & Cianciotto, N. P. (2001). Infect. Immun.69, 177–185. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Baron, G. S., Reilly, T. J. & Nano, F. E. (1999). FEMS Microbiol. Lett.176, 85–90. [DOI] [PubMed] [Google Scholar]
- Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N. & Bourne, P. E. (2000). Nucleic Acids Res.28, 235–242. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dennis, D. T., Inglesby, T. V., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Fine, A. D., Friedlander, A. M., Hauer, J., Layton, M., Lillibridge, S. R., McDade, J. E., Osterholm, M. T., O’Toole, T., Parker, G., Perl, T. M., Russell, P. K. & Tonat, K. (2001). JAMA, 285, 2763–2773. [DOI] [PubMed] [Google Scholar]
- Ellis, J., Oyston, P. C., Green, M. & Titball, R. W. (2002). Clin. Microbiol. Rev.15, 631–646. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Felts, R. L., Reilly, T. J. & Tanner, J. J. (2005). Biochim. Biophys. Acta, 1752, 107–110. [DOI] [PubMed] [Google Scholar]
- Gasteiger, E., Hoogland, C., Gattiker, A., Duvaud, S., Wilkins, M. R., Appel, R. D. & Bairoch, A. (2005). The Proteomics Protocols Handbook, edited by J. M. Walker, pp. 571–607. Totowa, NJ, USA: Humana Press.
- Jakob, C. G., Lewinski, K., Kuciel, R., Ostrowski, W. & Lebioda, L. (2000). Prostate, 42, 211–218. [DOI] [PubMed] [Google Scholar]
- Matthews, B. W. (1968). J. Mol. Biol.33, 491–497. [DOI] [PubMed] [Google Scholar]
- Oyston, P. C., Sjostedt, A. & Titball, R. W. (2004). Nature Rev. Microbiol.2, 967–978. [DOI] [PubMed]
- Pflugrath, J. W. (1999). Acta Cryst. D55, 1718–1725. [DOI] [PubMed] [Google Scholar]
- Redinbo, M. R. & Yeates, T. O. (1993). Acta Cryst. D49, 375–380. [DOI] [PubMed] [Google Scholar]
- Rees, D. C. (1980). Acta Cryst. A36, 578–581. [Google Scholar]
- Reilly, T. J., Baron, G. S., Nano, F. E. & Kuhlenschmidt, M. S. (1996). J. Biol. Chem.271, 10973–10983. [DOI] [PubMed] [Google Scholar]
- Reilly, T. J., Chance, D. L. & Smith, A. L. (1999). J. Bacteriol.181, 6797–6805. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Reilly, T. J., Felts, R. L., Henzl, M. T., Calcutt, M. J. & Tanner, J. J. (2006). Protein Exp. Purif.45, 132–141. [DOI] [PubMed]
- Vagin, A. & Teplyakov, A. (1997). J. Appl. Cryst.30, 1022–1025. [Google Scholar]
- Van Etten, R. L., Davidson, R., Stevis, P. E., MacArthur, H. & Moore, D. L. (1991). J. Biol. Chem.266, 2313–2319. [PubMed] [Google Scholar]